TY - JOUR
T1 - Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk
T2 - Results from the European Prospective Investigation into Cancer and Nutrition
AU - Allen, Naomi E.
AU - Key, Timothy J.
AU - Appleby, Paul N.
AU - Travis, Ruth C.
AU - Roddam, Andrew W.
AU - Rinaldi, Sabina
AU - Egevad, Lars
AU - Rohrmann, Sabine
AU - Linseisen, Jakob
AU - Pischon, Tobias
AU - Boeing, Heiner
AU - Johnsen, Nina Føns
AU - Tjønneland, Anne
AU - Grønbæk, Henning
AU - Overvad, Kim
AU - Kiemeney, Lambartus
AU - Bueno-de-Mesquita, H. Bas
AU - Bingham, Sheila
AU - Kay, Tee Khaw
AU - Tumino, Rosario
AU - Berrino, Franco
AU - Mattiello, Amalia
AU - Sacerdote, Carlotta
AU - Palli, Domenico
AU - Quirós, José Ramón
AU - Ardanaz, Eva
AU - Navarro, Carmen
AU - Larrañaga, Nerea
AU - Gonzalez, Carlos
AU - Sanchez, Maria José
AU - Trichopoulou, Antonia
AU - Travezea, Cryssoula
AU - Trichopoulos, Dimitrios
AU - Jenab, Mazda
AU - Ferrari, Pietro
AU - Riboli, Elio
AU - Kaaks, Rudolf
PY - 2007/6/1
Y1 - 2007/6/1
N2 - Background: Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer. Methods: We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression. Results: The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; P trend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; Ptrend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; Ptrend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; Ptrend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-I concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; Ptrend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; P trend = 0.11) for IGF-I adjusted for IGFBP-3. Conclusions: In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed.
AB - Background: Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer. Methods: We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression. Results: The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; P trend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; Ptrend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; Ptrend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; Ptrend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-I concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; Ptrend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; P trend = 0.11) for IGF-I adjusted for IGFBP-3. Conclusions: In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed.
UR - http://www.scopus.com/inward/record.url?scp=34250887614&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-06-1062
DO - 10.1158/1055-9965.EPI-06-1062
M3 - Article
SN - 1055-9965
VL - 16
SP - 1121
EP - 1127
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 6
ER -
